Who makes Phase 2: Optional ETN, SSZ, HCQ, MTX?

Phase 2: Optional ETN, SSZ, HCQ, MTX is developed by Pfizer.

What development phase is Phase 2: Optional ETN, SSZ, HCQ, MTX in?

Phase 2: Optional ETN, SSZ, HCQ, MTX is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Phase 2: Optional ETN, SSZ, HCQ, MTX

Pfizer · FDA-approved active Small molecule Quality 0/100

The drug, currently marketed by Pfizer, is in Phase 2 for optional use in combination with ETN, SSZ, HCQ, and MTX. A key strength is the protection of its composition patent, which expires in 2028. The primary risk is the lack of clear differentiation from competitors in the market.

At a glance

Generic name	Phase 2: Optional ETN, SSZ, HCQ, MTX
Sponsor	Pfizer
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Phase 2: Optional ETN, SSZ, HCQ, MTX CI brief — competitive landscape report
Phase 2: Optional ETN, SSZ, HCQ, MTX updates RSS · CI watch RSS
Pfizer portfolio CI